Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;36(4):493-507.
doi: 10.1111/ppe.12840. Epub 2022 Mar 2.

COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?

Helen Dolk  1 , Christine Damase-Michel  2 , Joan K Morris  3 , Maria Loane  1
Affiliations
Review

COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?

Helen Dolk et al. Paediatr Perinat Epidemiol. 2022 Jul.

Abstract

Background: The COVID-19 pandemic has accelerated pregnancy outcome research, but little attention has been given specifically to the risk of congenital anomalies (CA) and first trimester exposures.

Objectives: We reviewed the main data sources and study designs used internationally, particularly in Europe, for CA research, and their strengths and limitations for investigating COVID-19 disease, medications and vaccines.

Population: We classify research designs based on four data sources: a) spontaneous adverse event reporting, where study subjects are positive for both exposure and outcome, b) pregnancy exposure registries, where study subjects are positive for exposure, c) congenital anomaly registries, where study subjects are positive for outcome and d) population healthcare data where the entire population of births is included, irrespective of exposure and outcome.

Study design: Each data source allows different study designs, including case series, exposed pregnancy cohorts (with external comparator), ecological studies, case-control studies and population cohort studies (with internal comparator).

Methods: The quality of data sources for CA studies is reviewed in relation to criteria including diagnostic accuracy of CA data, size of study population, inclusion of terminations of pregnancy for foetal anomaly, inclusion of first trimester COVID-19-related exposures and use of an internal comparator group. Multinational collaboration models are reviewed.

Results: Pregnancy exposure registries have been the main design for COVID-19 pregnancy studies, but lack detail regarding first trimester exposures relevant to CA, or a suitable comparator group. CA registries present opportunities for improving diagnostic accuracy in COVID-19 research, especially when linked to other data sources. Availability of inpatient hospital medication use in population healthcare data is limited. More use of ongoing mother-baby linkage systems would improve research efficiency. Multinational collaboration delivers statistical power.

Conclusions: Challenges and opportunities exist to improve research on CA in relation to the COVID-19 pandemic and future pandemics.

Keywords: COVID-19; congenital anomalies; healthcare databases; pregnancy cohorts; registries; study design.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Types of data used in pregnancy pharmacovigilance with shaded area according to whether study subject selection is according to exposure to maternal medication/disease/vaccination, or according to presence of adverse pregnancy outcome (AO, Adverse Outcome; E, maternal exposure)
FIGURE 2
FIGURE 2
The Data Pyramid for research based on secondary use of data, from healthcare practitioners (HCPs) to study teams
See this image and copyright information in PMC

References

    1. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS‐CoV‐2 infection in UK: national population‐based cohort study. BMJ. 2020;369:m2107. - PMC - PubMed
    1. Delahoy MJ, Whitaker M, O’Halloran A, Chai SJ, Kirley PD, Alden N, et al. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory‐confirmed COVID‐19 — COVID‐NET, 13 States, March 1–August 22, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1347–1354. doi: 10.15585/mmwr.mm6938e1. - DOI - PMC - PubMed
    1. Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden's Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. AOGS Acta Obstet Gynecol Scand. 2020;99(7):819–822. - PMC - PubMed
    1. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. for PregCOV‐19 Living Systematic Review Consortium . Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta‐analysis. BMJ. 2020;1(370):m3320. doi: 10.1136/bmj.m3320. - DOI - PMC - PubMed
    1. Mitchell AA. Systematic identification of drugs that cause birth defects–a new opportunity. N Engl J Med. 2003;349(26):2556–9. doi: 10.1056/NEJMsb031395.2. - DOI - PubMed

Publication types